Literature DB >> 23645137

Evidence for a dysregulated immune system in the etiology of psychiatric disorders.

Sinead M Gibney1, Hemmo A Drexhage.   

Abstract

There is extensive bi-directional communication between the brain and the immune system in both health and disease. In recent years, the role of an altered immune system in the etiology of major psychiatric disorders has become more apparent. Studies have demonstrated that some patients with major psychiatric disorders exhibit characteristic signs of immune dysregulation and that this may be a common pathophysiological mechanism that underlies the development and progression of these disorders. Furthermore, many psychiatric disorders are also often accompanied by chronic medical conditions related to immune dysfunction such as autoimmune diseases, diabetes and atherosclerosis. One of the major psychiatric disorders that has been associated with an altered immune system is schizophrenia, with approximately one third of patients with this disorder showing immunological abnormalities such as an altered cytokine profile in serum and cerebrospinal fluid. An altered cytokine profile is also found in a proportion of patients with major depressive disorder and is thought to be potentially related to the pathophysiology of this disorder. Emerging evidence suggests that altered immune parameters may also be implicated in the neurobiological etiology of autism spectrum disorders. Further support for a role of immune dysregulation in the pathophysiology of these psychiatric disorders comes from studies showing the immunomodulating effects of antipsychotics and antidepressants, and the mood altering effects of anti-inflammatory therapies. This review will not attempt to discuss all of the psychiatric disorders that have been associated with an augmented immune system, but will instead focus on several key disorders where dysregulation of this system has been implicated in their pathophysiology including depression, schizophrenia and autism spectrum disorder.

Entities:  

Mesh:

Year:  2013        PMID: 23645137     DOI: 10.1007/s11481-013-9462-8

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  279 in total

1.  Amniotic fluid chemokines and autism spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort.

Authors:  Morsi W Abdallah; Nanna Larsen; Jakob Grove; Bent Nørgaard-Pedersen; Poul Thorsen; Erik L Mortensen; David M Hougaard
Journal:  Brain Behav Immun       Date:  2011-09-10       Impact factor: 7.217

Review 2.  Effects of prenatal infection on brain development and behavior: a review of findings from animal models.

Authors:  Patricia Boksa
Journal:  Brain Behav Immun       Date:  2010-03-15       Impact factor: 7.217

3.  Minocycline, schizophrenia and GluR1 glutamate receptors.

Authors:  Radmila Manev; Hari Manev
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-11-17       Impact factor: 5.067

Review 4.  Physiology of microglia.

Authors:  Helmut Kettenmann; Uwe-Karsten Hanisch; Mami Noda; Alexei Verkhratsky
Journal:  Physiol Rev       Date:  2011-04       Impact factor: 37.312

5.  Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome.

Authors:  Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac Pessah; Judy Van de Water
Journal:  Brain Behav Immun       Date:  2010-08-10       Impact factor: 7.217

6.  Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring.

Authors:  Stephen L Buka; Tyrone D Cannon; E Fuller Torrey; Robert H Yolken
Journal:  Biol Psychiatry       Date:  2007-11-05       Impact factor: 13.382

7.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

8.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

9.  Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice.

Authors:  Angela W Corona; Diana M Norden; John P Skendelas; Yan Huang; Jason C O'Connor; Marcus Lawson; Robert Dantzer; Keith W Kelley; Jonathan P Godbout
Journal:  Brain Behav Immun       Date:  2012-08-19       Impact factor: 7.217

10.  Immunological dysfunction in schizophrenia: a systematic approach.

Authors:  M Rothermundt; V Arolt; C Weitzsch; D Eckhoff; H Kirchner
Journal:  Neuropsychobiology       Date:  1998       Impact factor: 2.328

View more
  63 in total

Review 1.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

Review 2.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble.

Authors:  Eléonore Beurel; Marisa Toups; Charles B Nemeroff
Journal:  Neuron       Date:  2020-06-17       Impact factor: 17.173

3.  Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia.

Authors:  Jimmi Nielsen; Rasmus Røge; Sofie Gry Pristed; Anne Grethe Viuff; Henrik Ullum; Lise Wegner Thørner; Thomas Werge; Torkel Vang
Journal:  Schizophr Bull       Date:  2014-08-25       Impact factor: 9.306

Review 4.  The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders.

Authors:  Emily G Severance; Dag Tveiten; Lief H Lindström; Robert H Yolken; Karl L Reichelt
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

5.  Therapeutic effects of stress-programmed lymphocytes transferred to chronically stressed mice.

Authors:  Rachel B Scheinert; Mitra H Haeri; Michael L Lehmann; Miles Herkenham
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-04-21       Impact factor: 5.067

Review 6.  In-depth conversation: spectrum and kinetics of neuroimmune afferent pathways.

Authors:  Ning Quan
Journal:  Brain Behav Immun       Date:  2014-02-22       Impact factor: 7.217

7.  Impaired monocyte activation in schizophrenia: ultrastructural abnormalities and increased IL-1β production.

Authors:  Natalya A Uranova; P D Bonartsev; L V Androsova; V I Rakhmanova; V G Kaleda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-17       Impact factor: 5.270

8.  Lymphocytes from chronically stressed mice confer antidepressant-like effects to naive mice.

Authors:  Rebecca A Brachman; Michael L Lehmann; Dragan Maric; Miles Herkenham
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

9.  Exaggerated Increases in Microglia Proliferation, Brain Inflammatory Response and Sickness Behaviour upon Lipopolysaccharide Stimulation in Non-Obese Diabetic Mice.

Authors:  Barry McGuiness; Sinead M Gibney; Wouter Beumer; Marjan A Versnel; Inge Sillaber; Andrew Harkin; Hemmo A Drexhage
Journal:  Neuroimmunomodulation       Date:  2016-08-17       Impact factor: 2.492

Review 10.  Inflammatory profiles in the BTBR mouse: how relevant are they to autism spectrum disorders?

Authors:  Milo Careaga; Jared Schwartzer; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2014-06-14       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.